NEW YORK – The Canadian Cancer Trials Group on Monday said that it has opened a new protocol involving Treadwell Therapeutics' investigational PLK4 inhibitor, CFI-400945, within an ongoing Phase II umbrella trial.
NEW YORK – The Canadian Cancer Trials Group on Monday said that it has opened a new protocol involving Treadwell Therapeutics' investigational PLK4 inhibitor, CFI-400945, within an ongoing Phase II umbrella trial.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.